Distribution of poor-risk TP53 mutant MDS/AML vs good-risk TP53 mutant MDS according to Shah et al (92% vs 8%). Poor-risk TP53 mutant MDS/AML is identified by patients with a biallelic/multihit disease, complex karyotype, and ≥5% bone marrow myeloblasts, with the good-risk TP53 mutant patients not meeting any of these criteria. Current cohort also identified a VAF cutoff of 10% to best stratify survival, although multiple past cohorts have identified a VAF cutoff of 20% to 23% as the most optimal.

Distribution of poor-risk TP53 mutant MDS/AML vs good-risk TP53 mutant MDS according to Shah et al (92% vs 8%). Poor-risk TP53 mutant MDS/AML is identified by patients with a biallelic/multihit disease, complex karyotype, and ≥5% bone marrow myeloblasts, with the good-risk TP53 mutant patients not meeting any of these criteria. Current cohort also identified a VAF cutoff of 10% to best stratify survival, although multiple past cohorts have identified a VAF cutoff of 20% to 23% as the most optimal.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal